Liminatus Pharma, Inc. (LIMN)
3.78
+0.09
(+2.44%)
USD |
NASDAQ |
Oct 09, 16:00
3.78
0.00 (0.00%)
After-Hours: 20:00
Liminatus Pharma Total Liabilities (Quarterly) : 3.103M for June 30, 2026
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 3.103M |
| March 31, 2026 | 2.923M |
| December 31, 2025 | 10.33M |
| September 30, 2025 | 2.988M |
| June 30, 2025 | 10.72M |
| March 31, 2025 | 0.0011M |
| December 31, 2024 | 24.75M |
| September 30, 2024 | 17.32M |
| June 30, 2024 | 16.61M |
| March 31, 2024 | 17.16M |
| December 31, 2023 | 15.20M |
| September 30, 2023 | 14.76M |
| Date | Value |
|---|---|
| June 30, 2023 | 14.14M |
| March 31, 2023 | 14.38M |
| December 31, 2022 | 14.19M |
| September 30, 2022 | 12.18M |
| June 30, 2022 | 13.67M |
| March 31, 2022 | 17.66M |
| December 31, 2021 | 21.57M |
| September 30, 2021 | 21.65M |
| June 30, 2021 | 28.64M |
| March 31, 2021 | 28.90M |
| December 31, 2020 | 0.2753M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 436.29M |
| Alnylam Pharmaceuticals, Inc. | 4.205B |
| Anika Therapeutics, Inc. | 46.19M |
| Savara, Inc. | 48.48M |
| Vericel Corp. | 132.82M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 3.404M |
| Shareholders Equity (Quarterly) | 0.3006M |
| Debt to Equity Ratio | 4.799 |
| Current Ratio | 1.116 |
| Net Debt Paydown Yield | -233.3% |